Redeye provides a research update following the Q4 report recently published by Initiator Pharma.
Redeye comments on Oncopeptides’ Q4 report. Sales declined by 8% versus Q3 2025 when growth was expe...
Tradedoubler reported FY25 revenue growth of 5% (8% in constant currency), with another year of mode...
Fastighetsbolaget Trianons förvaltningsresultat per aktie ökade med 27 procent under 2025 jämfört me...
Case Group levererar på årsbasis fortsatt stark tillväxt och förbättrad lönsamhet i Q4 2025, med rob...
Redeye comments on Fable Media Group's proposal to distribute SEK 0.
Redeye considers Binero’s H2’25 results to be on the soft side of our expectations.
Hyresintäkterna steg 6,8% till 478,5 mkr drivet av indexeringar och uthyrningsgrad 99% (97%).
* Sales +12% vs. ABGSCe, EBIT SEK 1.2m (vs. 2.4m) * Recovery in OEM business after weaker Q2/Q3, sal...
Train Alliance's Q4 looks stable. Sale of land area in Hallsberg generated profit of SEK 44.
* Sales -1% vs cons, adj. EBITA -14%, but North America guided to grow in Q1e * 2026 guidance: "Bett...
Redeye expects a negative share price reaction to InfraCom's Q4 2025 results.
* We expect nearly 40% organic growth... * ...and gross margin expansion in '26e * Reiterate fair va...
Redeye comments on Formpipe’s Q4 report, which shows weak ACV but solid profitability.
Från ett spretigt bygge till en skalbar SaaS-maskin – Carasents historik och tidigare svaga sentimen...
Following the breakthrough license deal with Moderna, a global leader in mRNA therapeutics, in Q4’25...
Surgical Science delivered a decent but slightly soft Q4, facing near-term headwinds from the Intuit...
* An EBIT increase to SEK 6m (3m) in Q4'25 * We raise EBIT by 2-3% for '26e-'27e * Well positioned f...
* Orders +4%, sales +6%, adj. EBITA +15% vs. ABGSCe * Guides for 2.
Net sales and adj. EBITA were slightly below market consensus (LSEG) in Q4.